Advanced Neuromodulation Systems Receives European Approval for Rapid Programmer(R) 3.0 Clinician Programming Platform
January 17 2007 - 9:00AM
Business Wire
Advanced Neuromodulation Systems (ANS), the neuromodulation
business of St. Jude Medical, Inc. (NYSE:STJ), today announced
European CE Mark approval for its newest clinician programming
platform, Rapid Programmer 3.0 for spinal cord stimulation (SCS),
an advanced therapy for managing chronic pain. Coinciding with this
approval, ANS has launched an upgraded version of its rechargeable
spinal cord stimulation device, the Eon� with NeuroDynamix
technology. The Eon�s proprietary new microchip and enhanced
software, together with Rapid Programmer 3.0, create a
sophisticated system to provide patients with customized pain
coverage. Spinal cord stimulators like Eon are used to treat
patients suffering with chronic intractable pain. These �pacemakers
for pain� interrupt the pain signals� pathway to the brain by
delivering low intensity electrical pulses to selective nerve
fibers along the spinal cord. More than 30,000 patients worldwide
have been implanted with ANS neurostimulation systems to help
alleviate their chronic pain. �The enhanced Eon and the new Rapid
Programmer platform work together as an integrated system to
provide clinicians greater speed, power, efficiency and precision
for helping patients address complex pain,� said Chris Chavez,
president of Advanced Neuromodulation Systems. Rapid Programmer 3.0
features two new technologies for delivering stimulation to pain
patients: Dynamic MultiStim� � This technology allows for real-time
programming adjustments to multiple areas of pain, which better
targets pain coverage and decreases programming time. This is
especially useful when patients have complex pain patterns, such as
a combination of back and leg pain. Active Balancing� � This
capability lets patients and clinicians easily fine-tune
stimulation levels in multiple coverage areas, quickly establishing
relief and giving patients sophisticated, yet easy-to-use, control
over their therapy. The upgraded Eon stimulator provides the
longest time between recharges available today giving patients
added flexibility in their recharging schedule. Additionally, the
new Eon has market-leading power output, supplying 25 percent more
power than its predecessor and enabling it to meet the varying
power requirements of individual patients. The device also has the
highest frequency capability on the market, allowing it to serve
patients who need higher frequencies to control their pain. More
information for clinicians is available at
www.ans-medical.com/dynamicduo.com. About ANS, the Neuromodulation
Business of St. Jude Medical Advanced Neuromodulation Systems (ANS)
is an innovative technology leader dedicated to the design,
development, manufacturing and marketing of implantable
neuromodulation systems to improve the quality of life for people
suffering from disabling chronic pain and other nervous system
disorders. Based in Plano, Texas, ANS (www.ans-medical.com) is a
division of St. Jude Medical. About St. Jude Medical St. Jude
Medical is dedicated to making life better for cardiac,
neurological and chronic pain patients worldwide through excellence
in medical device technology and services. The Company has five
major focus areas that include: cardiac rhythm management, atrial
fibrillation, cardiac surgery, cardiology and neuromodulation.
Headquartered in St. Paul, Minn., St. Jude Medical employs more
than 11,000 people worldwide. For more information, please visit
www.sjm.com. Forward-Looking Statements This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that involve risks and
uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including
potential clinical successes, regulatory approvals, anticipated
future product launches, revenues, margins, earnings, and market
shares. The statements made by the Company are based upon
management�s current expectations and are subject to certain risks
and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include market conditions and other
factors beyond the Company�s control and the risk factors and other
cautionary statements described in the Company�s filings with the
SEC, including those described in the Company�s Annual Report on
Form 10-K filed on March 16, 2006 (see Item 1A on pages 15-21) and
in the Company�s Quarterly Reports on Form 10-Q filed on August 7,
2006 (see Item 1A on page 32) and November 7, 2006 (see pages
31-32). The Company does not intend to update these statements and
undertakes no duty to any person to provide any such update under
any circumstance.
SJM (NYSE:STJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Sep 2023 to Sep 2024